Sakar Healthcare Ltd
Sakar Healthcare Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and order book.
Sakar Healthcare Ltd Q4 FY26 key numbers
- Revenue
- Overall company aspires to achieve INR 500 crores revenue milestone within the next two years.
As stated in Sakar Healthcare Ltd's Q4 FY26 earnings call transcript · published 28 May 2026. Reported figures, not investment advice.
The short version
Sakar Healthcare targets INR 380 crores revenue in FY27, building on FY26's strong performance. Sakar Healthcare targets robust year-on-year growth, aiming to sustain around 40% revenue growth in FY27 driven by oncology and exports.
From Sakar Healthcare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Sakar Healthcare targets INR 380 crores revenue in FY27, building on FY26's strong performance.
- Oncology segment expected to nearly double sales to INR 200 crores in FY27 from around INR 95-100 crores in FY26.
- Overall company aspires to achieve INR 500 crores revenue milestone within the next two years.
- Export growth driven by tech transfer projects (e.g., 9 molecules with Accord, others with Torrent, Glenmark, Emcure) and own brand dossier registrations (~300+ dossiers globally).
- Expects export and domestic oncology sales split roughly 65% exports, 35% domestic in oncology, with oncology contributing 60% of total revenue.
- Capacity utilization in oncology plant to increase from ~29% to about 50-55% over two years.
2 more points from Sakar Healthcare Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Sakar Healthcare Ltd said on margins in the Q4 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Order Book & Pipeline
- Sakar Healthcare has a robust order pipeline, with over 300 product dossiers submitted across various regions including Europe, Australia, Africa, Southeast Asia, and Latin America.
- Specifically, 130+ oncology dossiers are under registration, with 12 approvals already received and more expected within the fiscal year.
- The company is commercializing 25 products expected to be registered by Q3 FY27, contributing significantly to export growth.
- Tech transfer projects include 9 molecules with partners like Accord, Torrent, Glenmark, Emcure, with 2 products already approved and supplies started; the remaining expected to be approved and commercialized gradually through FY27.
2 more points from Sakar Healthcare Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Sakar Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹87 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sakar Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
Sakar Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sakar Healthcare Ltd Q4 FY26 results?
Sakar Healthcare targets INR 380 crores revenue in FY27, building on FY26's strong performance. Sakar Healthcare targets robust year-on-year growth, aiming to sustain around 40% revenue growth in FY27 driven by oncology and exports.
What is Sakar Healthcare Ltd share price analysis?
Sakar Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.0 with a market cap of ₹1,949 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sakar Healthcare Ltd planning capital expenditure?
The transcript does not explicitly detail any specific current or future capex or strategic capital investments.
Keep Sakar Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.